Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, LVS Advisory - Growth. This analysis is provided for institutional research purposes only and is not investment advice.
"LVS Advisory delivered strong H1 2025 performance driven by its long-term investment in defense and nuclear player Curtiss-Wright and highly profitable event-driven arbitrage in biotech liquidations."
For the first half of 2025, the LVS Growth Portfolio returned 15.8% and the LVS Event-Driven Portfolio returned 3.6%, net of all fees, outperforming their respective S&P 500 and high-yield bond benchmarks. The letter highlights a core high-conviction holding in Curtiss-Wright (CW), an industrial conglomerate poised to benefit from structural growth in defense electronics, increased US naval spending, and a projected 5x earnings growth over the next 5-8 years in its commercial nuclear business. In parallel, the letter outlines its event-driven strategy focusing on biotech liquidations, illustrated by a profitable case study in iTeos Therapeutics (ITOS), which was purchased at a significant discount to its cash balance and is now on path to complete liquidation.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon